AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
AnaptysBio Q3 EPS $0.11 Misses $ 0.51 Estimate, Sales $30.274M Miss $33.186M Estimate
AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio: Fully Valued -- With Major Litigation Uncertainty
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60
AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.